ARCHIVES

Groups Advise NCI On “Investment Opportunities”

This article is from The Cancer Letter archive.

Vol. 22 No. 26 | June 28, 1996

Download PDF Visit The Full Archive

Related Articles

Appeals Court Overturns FDA Approval Of Generic Paclitaxel, A Setback For Ivax.

November 9, 2001

No Difference in Toxicity Between IMRT and PRT In Medicare Patients

January 25, 2013

A History of NCCN

January 13, 2012

Scientists, advocates voice objections to von Eschenbach’s conflicts, 2015.

November 23, 2005

BSA Approves Trial of Carbon Ion Therapy, Extends EDRN And Provocative Questions

July 4, 2014

Also: CALGB elects Schilsky to third term as chairman.

July 16, 2004